SAM
VNDA icon

Sawgrass Asset Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Sawgrass Asset Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-20,630
Closed -$354K – 312
2021
Q3 		$354K Sell
20,630
-720
-3% -$12.6K 0.04% 130
2021
Q2 		$459K Buy
21,350
+8,690
+69% +$156K 0.04% 118
2021
Q1 		$190K Buy
12,660
+1,410
+13% +$22.8K 0.02% 166
2020
Q4 		$148K Buy
+11,250
New +$135K 0.01% 165

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sawgrass Asset Management's VNDA Position: Q4 2021 in Review

Sawgrass Asset Management sold out of Vanda Pharmaceuticals (VNDA) in Q4 2021, closing a stake of 20,630 shares — an estimated $354K sold.

Sawgrass Asset Management first reported a position in VNDA in Q4 2020 and held it in 4 quarters. The position peaked at $459K in Q2 2021. 198 funds tracked by Wall St. Rank hold VNDA as of Q4 2021.

  • Sawgrass Asset Management reported no remaining Vanda Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Sawgrass Asset Management sold 20,630 Vanda Pharmaceuticals shares in Q4 2021, an estimated $354K.
  • Sawgrass Asset Management first reported a position in Vanda Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Sawgrass Asset Management's Vanda Pharmaceuticals position peaked at $459K in Q2 2021.
  • 198 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2021.

Based on Sawgrass Asset Management's 13F filing for Q4 2021, filed 3 Feb 2022.